# US 2011/0256636 A1 · Methods and reagents for diagnosing rheumatoid arthrtis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0256636 A1
- Document ID: US20110256636A1
- Status: Published application
- Kind: A1
- Application number: 13/086,528
- Filed: 2011-04-14
- Published: 2011-10-20
- Earliest claimed: 2010-04-16
- Assignees: Abbott Japan Co., Ltd.
- Inventors: Toru Yoshimura; Ryotaro Chiba
- Web page: https://patentgrep.com/patent/US20110256636A1

## CPC

- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- G01N 33/6854: {Immunoglobulins}
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described.

## Claims

### Claim 1

A method for diagnosing rheumatoid arthritis in a subject comprising measuring the level of CCL8 protein in a test sample obtained from the subject wherein the level of CCL8 protein in the test sample indicates presence or absence of rheumatoid arthritis in the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the presence or absence of rheumatoid arthritis is determined before clinical indicators of rheumatoid arthritis are present in the subject.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, wherein the level of CCL8 protein in the test sample is measured using an anti-CCL8 antibody.

### Claim 4 (depends on 1, 2)

The method according to claim 1 or 2, wherein the test sample is a plasma or a serum sample.

### Claim 5 (depends on 1, 2)

The method according to claim 1 or 2, further comprising measuring the level of one or more markers of rheumatoid arthritis in the sample wherein the markers are selected from the group consisting of: CRP, a-CCP, CARF IgG, MMP-3 and Rheumatoid factor, wherein the level of the one or markers in the test sample further indicates presence or absence of rheumatoid arthritis in the subject.

### Claim 6 (depends on 1, 2)

The method according to claim 1 or 2, wherein the level of CCL8 protein in the test sample is measured using a method selected from the group consisting of: mass spectrometry, high performance liquid chromatography, and two-dimensional electrophoresis.

### Claim 7

A method for determining the severity of rheumatoid arthritis in a subject comprising determining the presence or absence of an elevated level of CCL8 protein in a test sample obtained from the subject wherein the presence of an elevated level of CCL8 protein indicates that the rheumatoid arthritis in the subject is severe.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the level of CCL8 protein in the test sample is measured using an anti-CCL8 antibody.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the test sample is a plasma or a serum sample.

### Claim 10 (depends on 7)

The method according to claim 7, further comprising measuring the level of one or more markers of rheumatoid arthritis in the sample wherein the markers are selected from the group consisting of: CRP, a-CCP, CARF IgG, MMP-3 and Rheumatoid factor, wherein the level of the one or markers in the test sample further indicates presence or absence of rheumatoid arthritis in the subject.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the level of CCL8 protein in the test sample is measured using a method selected from the group consisting of: mass spectrometry, high performance liquid chromatography, and two-dimensional electrophoresis.

### Claim 12

A diagnostic reagent for rheumatoid arthritis comprising an anti-CCL8 antibody or fragment thereof, and an antibody against at least one marker of rheumatoid arthritis selected from the group consisting of: CRP, a-CCP, CARF IgG, MMP-3 and Rheumatoid factor.

### Claim 13 (depends on 12)

A kit comprising the diagnostic reagent of claim 12.

### Claim 14

A method for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis, comprising:
a. administering a test substance to an animal subject having an animal model of rheumatoid arthritis;
b. measuring the level of CCL8 protein in a test sample obtained from the animal subject; and
c. selecting the test substance as a candidate substance as a therapeutic agent for treating rheumatoid arthritis substance if the level of CCL8 protein in the test sample is lower than the level of CCL8 protein in a test sample from a comparable animal subject not administered the test substance.

### Claim 15

The use of an anti-CCL8 antibody or fragment thereof as a diagnostic reagent for the diagnosis of rheumatoid arthritis in a subject.

### Claim 16

The use of an anti-CCL8 antibody or fragment thereof as an active ingredient in a pharmaceutical composition for the treatment of rheumatoid arthritis in a subject.

### Claim 17

The use of an anti-CCL8 antibody or fragment thereof in the manufacture of a reagent for the diagnosis of rheumatoid arthritis in a subject.

### Claim 18

The use of an anti-CCL8 antibody or fragment thereof in the manufacture of a pharmaceutical composition for the treatment of rheumatoid arthritis in a subject.

### Claim 19

A method for monitoring the effect of a treatment of rheumatoid arthritis in a subject comprising:
a. measuring a first level of CCL8 protein in a first test sample obtained from the subject before the treatment;
b. measuring a second level of CCL8 protein in a second test sample obtained from the subject after the treatment begins;
c. comparing the first level of CCL8 protein and the second level of CCL8 protein, wherein a second level of CCL8 protein level that is lower than the first level of CCL8 protein is indicative of a therapeutic effect of the treatment in the subject.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the levels of CCL8 protein in the first and second test samples are measured using an anti-CCL8 antibody.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the test samples are plasma or serum samples.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the levels of CCL8 protein in the test samples are measured using a method selected from the group consisting of: mass spectrometry, high performance liquid chromatography, and two-dimensional electrophoresis.
